JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

Search

Glaukos Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

77.48 2.57

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

73.35

Max

77.82

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.5M

-20M

Pardavimai

17M

124M

Pelno marža

-15.837

Darbuotojai

995

EBITDA

12M

-8.6M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+59.36% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-10-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.1B

4.3B

Ankstesnė atidarymo kaina

74.91

Ankstesnė uždarymo kaina

77.48

Naujienos nuotaikos

By Acuity

44%

56%

140 / 373 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Glaukos Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-28 23:50; UTC

Karštos akcijos

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

2025-10-28 23:25; UTC

Uždarbis

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

2025-10-28 23:18; UTC

Uždarbis

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

2025-10-28 22:20; UTC

Uždarbis

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

2025-10-28 22:13; UTC

Uždarbis

Wal-Mart de Mexico Net Profit Falls in 3Q

2025-10-28 21:38; UTC

Uždarbis

Correction to Visa Sales Jump Article

2025-10-28 21:17; UTC

Uždarbis

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

2025-10-28 21:07; UTC

Uždarbis

Visa Sales Jump as Consumers Keep Spending -- Update

2025-10-28 21:02; UTC

Uždarbis

Mondelez Tempers Outlook as Costs Rise

2025-10-28 23:51; UTC

Rinkos pokalbiai

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

2025-10-28 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

2025-10-28 23:02; UTC

Uždarbis

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

2025-10-28 23:01; UTC

Uždarbis

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

2025-10-28 22:46; UTC

Uždarbis

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

2025-10-28 22:45; UTC

Uždarbis

SK Hynix 3Q Net KRW12.6T >000660.SE

2025-10-28 22:44; UTC

Uždarbis

SK Hynix 3Q Rev KRW24.44T >000660.SE

2025-10-28 22:43; UTC

Uždarbis

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

2025-10-28 22:42; UTC

Uždarbis

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

2025-10-28 22:40; UTC

Uždarbis

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

2025-10-28 22:40; UTC

Uždarbis

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

2025-10-28 22:20; UTC

Uždarbis

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

2025-10-28 22:02; UTC

Uždarbis

Review & Preview: Earnings Extravaganza -- Barrons.com

2025-10-28 21:42; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-10-28 21:42; UTC

Rinkos pokalbiai
Uždarbis

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

2025-10-28 21:20; UTC

Uždarbis

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

2025-10-28 21:19; UTC

Uždarbis

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

2025-10-28 21:18; UTC

Uždarbis

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Akcijų palyginimas

Kainos pokytis

Glaukos Corp Prognozė

Kainos tikslas

By TipRanks

59.36% į viršų

12 mėnesių prognozė

Vidutinis 120.6 USD  59.36%

Aukščiausias 165 USD

Žemiausias 103 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Glaukos Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

12

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

87.61 / 93Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

140 / 373 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat